| Motif ID |
Motif Logo |
Scanned Score Distribution |
Frequency of Motif |
Replicability Score |
Evolutionary Conservation Score |
Gene Targets |
Gene Ontology of CpGMM targets |
| CG_ffipsc1911_promoter_n_PM_14_7_4 |
 |
 |
3 |
0.6 |
2.60E-05 |
ERCC2,
ACD,
UNC13D |
granuloma formation [BP],
positive regulation of DNA binding [BP],
positive regulation of single-stranded telomeric DNA binding [BP] |
| CG_ffipsc1911_promoter_n_PM_14_77_13 |
 |
 |
3 |
0.6 |
2.07E-05 |
KCNN4,
HAO1 |
glyoxylate oxidase activity [MF],
glycolate catabolic process [BP],
stabilization of membrane potential [BP],
glycolate oxidase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_16_3_15 |
 |
 |
4 |
0.8 |
2.81E-05 |
SLC30A2,
BRCA1 |
positive regulation of histone H4-K20 methylation [BP],
positive regulation of histone H3-K9 acetylation [BP],
positive regulation of sequestering of zinc ion [BP],
positive regulation of histone H4-K16 acetylation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_177_5 |
 |
 |
4 |
0.8 |
7.44E-05 |
CLIP1,
TUBGCP2,
IL18 |
macropinosome [CC],
positive regulation of male germ cell proliferation [BP],
positive regulation of tissue remodeling [BP],
cytoplasmic microtubule [CC] |
| CG_ffipsc1911_promoter_n_PM_12_216_5 |
 |
 |
3 |
0.6 |
3.56E-05 |
ARHGAP17,
KLF4,
PLA2G1B,
SYMPK |
tight junction [CC],
negative regulation of chemokine (C-X-C motif) ligand 2 production [BP],
positive regulation of hemoglobin biosynthetic process [BP],
negative regulation of muscle hyperplasia [BP],
sequence-specific DNA binding transcription factor recruiting transcription factor activity [MF],
interleukin-8 production [BP] |
| CG_ffipsc1911_promoter_n_PM_12_40_9 |
 |
 |
4 |
0.8 |
1.52E-04 |
AKR7A2,
SLC6A3 |
phenanthrene-9,10-epoxide hydrolase activity [MF],
dopamine:sodium symporter activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_114_11 |
 |
 |
3 |
0.6 |
4.42E-05 |
PIP4K2B,
DDAH1 |
1-phosphatidylinositol-5-phosphate 4-kinase activity [MF],
dimethylargininase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_14_17_13 |
 |
 |
4 |
0.8 |
6.52E-05 |
CHEK2,
DEGS2 |
signal transduction involved in intra-S DNA damage checkpoint [BP],
sphingolipid delta-4 desaturase activity [MF],
sphingosine hydroxylase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_32_5 |
 |
 |
2 |
0.4 |
1.47E-04 |
CYBA,
ELL,
ZFYVE1 |
smooth muscle hypertrophy [BP],
negative regulation of glomerular filtration by angiotensin [BP],
negative regulation of phosphatase activity [BP] |
| CG_ffipsc1911_promoter_n_PM_14_67_6 |
 |
 |
1 |
0.2 |
2.69E-05 |
BAZ2A |
heterochromatin assembly involved in chromatin silencing [BP] |
| CG_ffipsc1911_promoter_n_PM_12_186_8 |
 |
 |
2 |
0.4 |
3.25E-04 |
SHPK,
ARPC3 |
regulation of actin filament polymerization [BP],
cellular response to interleukin-13 [BP],
sedoheptulokinase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_14_42_17 |
 |
 |
6 |
1.0 |
4.26E-05 |
TNFRSF1A,
IL6ST,
PLA2G4C |
glycerophospholipid catabolic process [BP],
positive regulation of tyrosine phosphorylation of Stat1 protein [BP] |
| CG_ffipsc1911_promoter_n_PM_18_4_10 |
 |
 |
4 |
0.8 |
5.26E-05 |
IL1B,
MCM6 |
sequestering of triglyceride [BP],
MCM complex [CC] |
| CG_ffipsc1911_promoter_n_PM_18_18_28 |
 |
 |
4 |
0.8 |
9.65E-05 |
YWHAE,
NEDD4 |
phosphoserine binding [MF] |
| CG_ffipsc1911_promoter_n_PM_16_21_10 |
 |
 |
2 |
0.4 |
1.79E-05 |
ALG5,
CBS |
cysteine biosynthetic process via cystathionine [BP],
dolichyl-phosphate beta-glucosyltransferase activity [MF],
cystathionine beta-synthase activity [MF],
cysteine biosynthetic process from serine [BP],
homocysteine catabolic process [BP] |
| CG_ffipsc1911_promoter_n_PM_18_21_13 |
 |
 |
4 |
0.8 |
5.85E-05 |
HMGCL |
response to starvation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_221_11 |
 |
 |
2 |
0.4 |
1.75E-04 |
HTR2A |
phospholipase C-activating serotonin receptor signaling pathway [BP] |
| CG_ffipsc1911_promoter_n_PM_12_145_13 |
 |
 |
2 |
0.4 |
7.35E-05 |
CMA1,
NHP2,
CYP11B2 |
regulation of blood volume by renal aldosterone [BP],
steroid 11-beta-monooxygenase activity [MF],
corticosterone 18-monooxygenase activity [MF],
interleukin-1 beta biosynthetic process [BP],
rRNA pseudouridine synthesis [BP] |
| CG_ffipsc1911_promoter_n_PM_12_124_15 |
 |
 |
3 |
0.4 |
4.10E-05 |
HSPA5,
SLC27A5 |
regulation of protein folding in endoplasmic reticulum [BP],
cholate-CoA ligase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_17_4 |
 |
 |
1 |
0.2 |
3.79E-05 |
UBC |
hypothalamus gonadotrophin-releasing hormone neuron development [BP] |
| CG_ffipsc1911_promoter_n_PM_12_48_5 |
 |
 |
2 |
0.4 |
9.22E-05 |
ADCY5 |
water transport [BP] |
| CG_ffipsc1911_promoter_n_PM_14_61_5 |
 |
 |
2 |
0.4 |
1.13E-04 |
NACA |
negative regulation of transcription from RNA polymerase II promoter involved in heart development [BP],
positive regulation of skeletal muscle tissue growth [BP],
nascent polypeptide-associated complex [CC] |
| CG_ffipsc1911_promoter_n_PM_12_207_9 |
 |
 |
2 |
0.4 |
3.87E-05 |
LTA4H |
leukotriene-A4 hydrolase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_14_59_7 |
 |
 |
3 |
0.6 |
4.96E-05 |
NCKIPSD,
VPRBP,
SLC11A2 |
vanadium ion transmembrane transporter activity [MF],
paraferritin complex [CC],
nickel cation transport [BP],
cadmium ion transmembrane transporter activity [MF],
ferrous iron import [BP],
lead ion transport [BP],
ferrous iron transport [BP],
nickel cation transmembrane transport [BP],
signalosome [CC],
lead ion transmembrane transporter activity [MF],
vanadium ion transport [BP] |
| CG_ffipsc1911_promoter_n_PM_12_182_7 |
 |
 |
3 |
0.6 |
7.88E-05 |
CHD8,
MCRS1,
SPRY2 |
MLL1 complex [CC],
negative regulation of Ras protein signal transduction [BP] |
| CG_ffipsc1911_promoter_n_PM_12_168_7 |
 |
 |
1 |
0.2 |
1.29E-04 |
TK2,
UNC13D |
granuloma formation [BP],
deoxycytidine metabolic process [BP] |
| CG_ffipsc1911_promoter_n_PM_12_265_6 |
 |
 |
2 |
0.4 |
1.93E-04 |
ARNT,
SYNE4 |
integral to nuclear outer membrane [CC],
aryl hydrocarbon receptor activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_217_8 |
 |
 |
2 |
0.4 |
4.50E-05 |
OSR1,
TOP2A,
RELN |
metanephric smooth muscle tissue development [BP],
metanephric cap mesenchymal cell proliferation involved in metanephros development [BP],
positive regulation of retroviral genome replication [BP],
mitotic cell cycle G2/M transition decatenation checkpoint [BP],
specification of posterior mesonephric tubule identity [BP],
positive regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity [BP],
DNA topoisomerase complex (ATP-hydrolyzing) [CC],
viral integration complex [CC],
intermediate mesoderm development [BP],
renal vesicle progenitor cell differentiation [BP],
specification of anterior mesonephric tubule identity [BP],
posterior mesonephric tubule development [BP],
metanephric interstitial cell development [BP],
positive regulation of long-term synaptic potentiation [BP] |
| CG_ffipsc1911_promoter_n_PM_18_24_24 |
 |
 |
1 |
0.2 |
6.35E-05 |
POLQ |
single-stranded DNA-dependent ATPase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_22_10 |
 |
 |
3 |
0.6 |
1.06E-04 |
SLC19A1 |
methotrexate transport [BP],
methotrexate transporter activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_99_3 |
 |
 |
1 |
0.2 |
5.12E-05 |
RELA,
PKD1L1,
SHH |
response to cobalamin [BP],
negative regulation of ureter smooth muscle cell differentiation [BP],
hair follicle development [BP],
myoblast differentiation [BP],
right lung development [BP],
negative regulation of protein catabolic process [BP],
multicellular structure septum development [BP],
epithelial-mesenchymal signaling involved in prostate gland development [BP],
primary prostatic bud elongation [BP],
positive regulation of kidney smooth muscle cell differentiation [BP],
CD4-positive or CD8-positive, alpha-beta T cell lineage commitment [BP],
intein-mediated protein splicing [BP],
detection of nodal flow [BP],
positive regulation of skeletal muscle cell proliferation [BP],
negative regulation of kidney smooth muscle cell differentiation [BP],
positive regulation of epithelial cell proliferation involved in prostate gland development [BP],
acetaldehyde metabolic process [BP],
mesenchymal smoothened signaling pathway involved in prostate gland development [BP],
regulation of mesenchymal cell proliferation involved in prostate gland development [BP],
positive regulation of Schwann cell differentiation [BP],
positive regulation of ureter smooth muscle cell differentiation [BP],
positive regulation of sclerotome development [BP] |
| CG_ffipsc1911_promoter_n_PM_12_44_8 |
 |
 |
2 |
0.4 |
5.52E-04 |
ADPRHL1 |
protein de-ADP-ribosylation [BP],
ADP-ribosylarginine hydrolase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_203_5 |
 |
 |
2 |
0.4 |
4.82E-05 |
TRIM3,
RAB24,
TMEM48,
RAB20 |
nuclear pore distribution [BP],
protein transport [BP] |
| CG_ffipsc1911_promoter_n_PM_14_22_10 |
 |
 |
1 |
0.2 |
5.36E-06 |
ECE1 |
Weibel-Palade body [CC],
substance P catabolic process [BP],
calcitonin catabolic process [BP],
intrinsic to endosome membrane [CC],
endothelin maturation [BP] |
| CG_ffipsc1911_promoter_n_PM_14_65_9 |
 |
 |
3 |
0.6 |
1.78E-04 |
ARFGEF1 |
positive regulation of protein glycosylation in Golgi [BP],
endomembrane system organization [BP],
protein kinase A regulatory subunit binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_46_9 |
 |
 |
2 |
0.4 |
2.36E-05 |
AGA,
EIF6,
SACS |
ribosomal subunit export from nucleus [BP],
ribosomal large subunit binding [MF],
negative regulation of inclusion body assembly [BP],
N4-(beta-N-acetylglucosaminyl)-L-asparaginase activity [MF],
cell body fiber [CC],
protein deglycosylation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_97_5 |
 |
 |
1 |
0.2 |
8.18E-05 |
SSTR3,
APRT |
AMP salvage [BP],
adenine binding [MF],
adenine salvage [BP],
adenine phosphoribosyltransferase activity [MF],
somatostatin signaling pathway [BP] |
| CG_ffipsc1911_promoter_n_PM_14_47_13 |
 |
 |
7 |
1.0 |
5.52E-06 |
MMS19 |
CIA complex [CC],
phosphorelay signal transduction system [BP] |
| CG_ffipsc1911_promoter_n_PM_12_266_5 |
 |
 |
4 |
0.8 |
8.64E-05 |
GAS6 |
cellular response to vitamin K [BP],
negative regulation of renal albumin absorption [BP],
negative regulation of oligodendrocyte apoptotic process [BP] |
| CG_ffipsc1911_promoter_n_PM_12_115_11 |
 |
 |
2 |
0.4 |
8.41E-05 |
GAMT,
FOLH1,
NDUFB7,
PTGR1,
BLMH,
TSC1,
ELMO1,
GCSH,
KCNJ11 |
2-alkenal reductase [NAD(P)] activity [MF],
guanidinoacetate N-methyltransferase activity [MF],
actin cytoskeleton organization [BP],
rRNA export from nucleus [BP],
small molecule metabolic process [BP],
glycine decarboxylation via glycine cleavage system [BP],
carboxypeptidase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_248_9 |
 |
 |
2 |
0.4 |
1.59E-05 |
PPP2CA,
RBP4,
SBF1 |
retinol transporter activity [MF],
protein dephosphorylation [BP],
female genitalia morphogenesis [BP],
retinol transport [BP] |
| CG_ffipsc1911_promoter_n_PM_12_65_7 |
 |
 |
2 |
0.4 |
4.43E-05 |
ART4,
DOCK4,
CRLF1,
HNF1B |
negative regulation of motor neuron apoptotic process [BP],
positive regulation of Rac GTPase activity [BP],
arginine metabolic process [BP],
regulation of pronephros size [BP] |
| CG_ffipsc1911_promoter_n_PM_18_17_16 |
 |
 |
4 |
0.8 |
1.69E-05 |
UROS,
ITPK1 |
inositol tetrakisphosphate 1-kinase activity [MF],
inositol-1,3,4-trisphosphate 6-kinase activity [MF],
uroporphyrinogen-III synthase activity [MF],
inositol-1,3,4-trisphosphate 5-kinase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_143_9 |
 |
 |
3 |
0.6 |
1.63E-04 |
ROCK2 |
regulation of focal adhesion assembly [BP] |
| CG_ffipsc1911_promoter_n_PM_12_89_6 |
 |
 |
2 |
0.4 |
9.25E-05 |
NAGA |
alpha-galactosidase activity [MF],
alpha-N-acetylgalactosaminidase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_108_17 |
 |
 |
5 |
0.8 |
2.72E-04 |
DALRD3 |
arginyl-tRNA aminoacylation [BP],
arginine-tRNA ligase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_16_34_15 |
 |
 |
5 |
1.0 |
4.97E-05 |
FLCN,
RHEBL1,
PPP1R15B,
GPATCH8,
TP53,
EDF1 |
intracellular [CC],
ER overload response [BP],
TOR signaling cascade [BP] |
| CG_ffipsc1911_promoter_n_PM_12_166_5 |
 |
 |
1 |
0.2 |
1.33E-05 |
PEX6,
PPP4R1 |
protein import into peroxisome matrix, translocation [BP],
protein phosphatase type 4 regulator activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_173_12 |
 |
 |
2 |
0.4 |
6.97E-05 |
ODC1,
LTA4H |
putrescine biosynthetic process from ornithine [BP],
leukotriene-A4 hydrolase activity [MF],
ornithine decarboxylase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_26_8 |
 |
 |
2 |
0.4 |
3.96E-05 |
PIF1,
SLC2A5 |
fructose transmembrane transporter activity [MF],
ATP-dependent 5'-3' DNA/RNA helicase activity [MF],
fructose transport [BP],
single-stranded DNA-dependent ATP-dependent DNA helicase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_16_6_9 |
 |
 |
3 |
0.6 |
6.36E-05 |
CCNB1IP1 |
meiotic metaphase I [BP] |
| CG_ffipsc1911_promoter_n_PM_12_81_11 |
 |
 |
3 |
0.6 |
2.98E-04 |
ATP13A4,
ATP5O |
ATP biosynthetic process [BP] |
| CG_ffipsc1911_promoter_n_PM_16_28_13 |
 |
 |
3 |
0.6 |
2.58E-05 |
OVGP1,
L2HGDH,
GSS,
PC,
PSG9,
PSG2,
PSG3,
PGF |
2-hydroxyglutarate dehydrogenase activity [MF],
glutathione synthase activity [MF],
female pregnancy [BP],
pyruvate carboxylase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_198_7 |
 |
 |
1 |
0.2 |
6.86E-05 |
SLA2,
SMARCC1 |
protein N-terminus binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_151_4 |
 |
 |
1 |
0.2 |
5.47E-05 |
NEBL |
cardiac muscle thin filament assembly [BP] |
| CG_ffipsc1911_promoter_n_PM_12_61_4 |
 |
 |
2 |
0.4 |
9.97E-05 |
DPAGT1 |
phospho-N-acetylmuramoyl-pentapeptide-transferase activity [MF],
UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase activity [MF],
dolichol biosynthetic process [BP] |
| CG_ffipsc1911_promoter_n_PM_14_25_9 |
 |
 |
2 |
0.4 |
6.95E-05 |
FBXW4,
SHH |
embryonic digit morphogenesis [BP],
mesenchymal smoothened signaling pathway involved in prostate gland development [BP],
positive regulation of mesenchymal cell proliferation [BP],
regulation of mesenchymal cell proliferation involved in prostate gland development [BP],
positive regulation of skeletal muscle cell proliferation [BP],
negative regulation of kidney smooth muscle cell differentiation [BP],
multicellular structure septum development [BP],
negative regulation of ureter smooth muscle cell differentiation [BP],
positive regulation of ureter smooth muscle cell differentiation [BP],
positive regulation of sclerotome development [BP],
positive regulation of kidney smooth muscle cell differentiation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_52_11 |
 |
 |
2 |
0.4 |
1.31E-05 |
SNX8,
CBS |
L-serine catabolic process [BP],
cystathionine beta-synthase activity [MF],
early endosome to Golgi transport [BP],
cysteine biosynthetic process via cystathionine [BP],
homocysteine catabolic process [BP],
transsulfuration [BP],
cysteine biosynthetic process from serine [BP],
hydrogen sulfide biosynthetic process [BP],
L-cysteine catabolic process [BP] |
| CG_ffipsc1911_promoter_n_PM_12_153_4 |
 |
 |
2 |
0.4 |
1.36E-04 |
LPHN1,
DDC |
cell adhesion molecule binding [MF],
aromatic-L-amino-acid decarboxylase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_133_10 |
 |
 |
2 |
0.4 |
2.13E-04 |
AIM2 |
pyroptosis [BP] |
| CG_ffipsc1911_promoter_n_PM_12_98_11 |
 |
 |
2 |
0.4 |
2.95E-04 |
SLC25A2 |
mitochondrial ornithine transport [BP] |
| CG_ffipsc1911_promoter_n_PM_12_162_4 |
 |
 |
4 |
0.8 |
3.40E-05 |
SDF4,
NDRG2,
CHCHD4,
LIF |
negative regulation of ERK1 and ERK2 cascade [BP],
protein import into mitochondrial intermembrane space [BP],
zymogen granule exocytosis [BP],
positive regulation of histone H3-K27 acetylation [BP],
positive regulation of protein localization to nucleus [BP],
RNA polymerase II transcription factor recruiting transcription factor activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_271_12 |
 |
 |
1 |
0.2 |
4.03E-05 |
HYAL2,
C3,
BAK1,
SLC6A3 |
cellular response to UV [BP],
aging [BP],
dopamine:sodium symporter activity [MF],
C5L2 anaphylatoxin chemotactic receptor binding [MF],
response to mycotoxin [BP],
receptor signaling protein tyrosine kinase inhibitor activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_218_12 |
 |
 |
2 |
0.4 |
7.55E-05 |
ZBTB17,
TLN1,
PDLIM7 |
activation of signaling protein activity involved in unfolded protein response [BP],
focal adhesion [CC],
endoplasmic reticulum unfolded protein response [BP],
ruffle [CC] |
| CG_ffipsc1911_promoter_n_PM_12_67_8 |
 |
 |
3 |
0.6 |
1.35E-04 |
INTS1 |
U2 snRNA 3'-end processing [BP] |
| CG_ffipsc1911_promoter_n_PM_16_33_25 |
 |
 |
5 |
1.0 |
1.51E-05 |
UBE2G1,
RNF6 |
protein K48-linked ubiquitination [BP] |
| CG_ffipsc1911_promoter_n_PM_12_184_8 |
 |
 |
2 |
0.4 |
1.59E-04 |
NCAPD3 |
nuclear condensin complex [CC] |
| CG_ffipsc1911_promoter_n_PM_12_33_5 |
 |
 |
2 |
0.4 |
8.37E-05 |
AGA,
OVCH1,
CTSG,
PARL |
serine-type endopeptidase activity [MF],
peptidase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_178_9 |
 |
 |
2 |
0.4 |
3.64E-04 |
CLPX |
mitochondrial endopeptidase Clp complex [CC] |
| CG_ffipsc1911_promoter_n_PM_12_11_11 |
 |
 |
2 |
0.4 |
8.58E-05 |
LONP1,
TSTA3 |
mitochondrial heavy strand promoter anti-sense binding [MF],
GDP-L-fucose synthase activity [MF],
GDP-4-dehydro-D-rhamnose reductase activity [MF],
mitochondrial light strand promoter anti-sense binding [MF] |
| CG_ffipsc1911_promoter_n_PM_14_66_8 |
 |
 |
1 |
0.2 |
1.09E-04 |
C1QTNF3 |
negative regulation of interleukin-6 secretion [BP],
positive regulation of adiponectin secretion [BP],
negative regulation of monocyte chemotactic protein-1 production [BP] |
| CG_ffipsc1911_promoter_n_PM_12_14_4 |
 |
 |
2 |
0.4 |
1.17E-04 |
GBGT1,
LEMD2,
DNAJC2,
SULT1E1 |
nuclear membrane [CC],
estrone sulfotransferase activity [MF],
globoside alpha-N-acetylgalactosaminyltransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_14_37_5 |
 |
 |
1 |
0.2 |
8.99E-05 |
TMEM229A |
host cell nucleus [CC] |
| CG_ffipsc1911_promoter_n_PM_18_29_12 |
 |
 |
2 |
0.4 |
1.17E-05 |
SPC24 |
Ndc80 complex [CC] |
| CG_ffipsc1911_promoter_n_PM_12_60_11 |
 |
 |
3 |
0.6 |
2.71E-05 |
DCAKD,
ARSA,
SGSH,
MCL1 |
protein channel activity [MF],
N-sulfoglucosamine sulfohydrolase activity [MF],
dephospho-CoA kinase activity [MF],
cerebroside-sulfatase activity [MF],
lysosomal lumen [CC],
sulfuric ester hydrolase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_14_60_7 |
 |
 |
4 |
0.8 |
1.20E-05 |
H2AFX,
BUB1,
TUBB8,
XRCC1 |
damaged DNA binding [MF],
regulation of chromosome segregation [BP],
protein polymerization [BP] |
| CG_ffipsc1911_promoter_n_PM_14_69_7 |
 |
 |
1 |
0.2 |
9.95E-05 |
CDC37,
SUMO1 |
interferon-gamma-mediated signaling pathway [BP],
protein localization to nuclear pore [BP],
regulation of interferon-gamma-mediated signaling pathway [BP] |
| CG_ffipsc1911_promoter_n_PM_14_49_11 |
 |
 |
2 |
0.4 |
9.10E-05 |
SUMO1,
NOTCH3,
PRPF19 |
negative regulation of neuron differentiation [BP],
protein localization to nuclear pore [BP] |
| CG_ffipsc1911_promoter_n_PM_12_252_9 |
 |
 |
3 |
0.6 |
7.16E-05 |
APOB,
PRLR |
prolactin signaling pathway [BP],
mature chylomicron [CC],
endosome lumen [CC],
chylomicron remnant [CC],
prolactin receptor activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_9_8 |
 |
 |
2 |
0.4 |
1.87E-05 |
MBP |
internode region of axon [CC] |
| CG_ffipsc1911_promoter_n_PM_18_13_12 |
 |
 |
4 |
0.8 |
5.54E-05 |
TGM5,
TEFM,
DDX6,
ATXN2,
AGO2,
TGM2 |
cytoplasmic mRNA processing body assembly [BP],
polysome [CC],
protein-glutamine gamma-glutamyltransferase activity [MF],
peptide cross-linking [BP],
RNA-induced silencing complex [CC],
cytoplasmic stress granule [CC],
ribonucleoprotein complex [CC] |
| CG_ffipsc1911_promoter_n_PM_18_2_15 |
 |
 |
3 |
0.6 |
7.10E-05 |
FGF10,
RBP4,
GATA2 |
semicircular canal development [BP],
female genitalia morphogenesis [BP] |
| CG_ffipsc1911_promoter_n_PM_14_29_12 |
 |
 |
4 |
0.8 |
7.58E-05 |
MPO |
hypochlorous acid biosynthetic process [BP] |
| CG_ffipsc1911_promoter_n_PM_12_96_7 |
 |
 |
3 |
0.6 |
1.09E-04 |
TRPV4 |
osmosensor activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_116_4 |
 |
 |
2 |
0.4 |
1.73E-04 |
PIK3IP1,
PYCARD |
positive regulation of antigen processing and presentation of peptide antigen via MHC class II [BP],
negative regulation of phosphatidylinositol 3-kinase activity [BP],
phosphatidylinositol 3-kinase catalytic subunit binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_267_5 |
 |
 |
2 |
0.4 |
1.33E-04 |
PNKP,
SNAPC4,
UCN |
snRNA transcription from RNA polymerase III promoter [BP],
nucleotide phosphorylation [BP],
gastric emptying [BP],
snRNA transcription from RNA polymerase II promoter [BP],
snRNA-activating protein complex [CC] |
| CG_ffipsc1911_promoter_n_PM_16_15_14 |
 |
 |
3 |
0.6 |
6.46E-05 |
RPS10,
PSMD12,
BAZ1A,
HNRNPL,
CHEK2,
CEBPA |
ACF complex [CC],
signal transduction involved in intra-S DNA damage checkpoint [BP],
gene expression [BP],
RNA metabolic process [BP],
response to vitamin B2 [BP] |
| CG_ffipsc1911_promoter_n_PM_18_26_14 |
 |
 |
4 |
0.8 |
3.93E-05 |
NACA,
GSK3A,
ROCK2,
APH1A |
membrane protein ectodomain proteolysis [BP],
negative regulation of transcription from RNA polymerase II promoter involved in heart development [BP],
negative regulation of UDP-glucose catabolic process [BP],
positive regulation of centrosome duplication [BP] |
| CG_ffipsc1911_promoter_n_PM_12_142_15 |
 |
 |
2 |
0.4 |
7.89E-05 |
ADAT1,
TPP1 |
tRNA-specific adenosine deaminase activity [MF],
tripeptidyl-peptidase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_34_6 |
 |
 |
2 |
0.4 |
1.99E-04 |
CYP11B2 |
corticosterone 18-monooxygenase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_250_9 |
 |
 |
1 |
0.2 |
5.49E-05 |
PRDM5,
TGFB1 |
defense response to fungus, incompatible interaction [BP],
negative regulation of hyaluronan biosynthetic process [BP],
positive regulation of NAD+ ADP-ribosyltransferase activity [BP],
histone deacetylation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_88_3 |
 |
 |
1 |
0.2 |
1.73E-04 |
ZSWIM7,
PODXL |
Shu complex [CC],
regulation of microvillus assembly [BP] |
| CG_ffipsc1911_promoter_n_PM_12_148_6 |
 |
 |
2 |
0.4 |
1.53E-04 |
MAGEC2,
AXIN1,
SLC25A29 |
canonical Wnt receptor signaling pathway involved in neural plate anterior/posterior pattern formation [BP],
acyl carnitine transmembrane transporter activity [MF],
positive regulation of ubiquitin-protein ligase activity [BP],
Wnt receptor signaling pathway involved in forebrain neuron fate commitment [BP] |
| CG_ffipsc1911_promoter_n_PM_14_73_15 |
 |
 |
3 |
0.4 |
1.03E-04 |
ARFRP1 |
protein localization to Golgi apparatus [BP] |
| CG_ffipsc1911_promoter_n_PM_16_4_68 |
 |
 |
6 |
1.0 |
5.20E-05 |
SLC4A11 |
bicarbonate transmembrane transporter activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_5_4 |
 |
 |
1 |
0.2 |
9.51E-05 |
NPC1,
FNBP1,
SNX5,
STOML2,
PPT1 |
pinocytosis [BP],
endocytosis [BP],
cardiolipin binding [MF] |
| CG_ffipsc1911_promoter_n_PM_16_43_18 |
 |
 |
3 |
0.6 |
2.94E-05 |
CTSH |
HLA-A specific activating MHC class I receptor activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_29_11 |
 |
 |
4 |
0.8 |
1.31E-04 |
WNT7A,
CRH |
ferulate metabolic process [BP],
corticotropin-releasing hormone activity [MF],
Wnt receptor signaling pathway involved in wound healing, spreading of epidermal cells [BP] |
| CG_ffipsc1911_promoter_n_PM_12_210_13 |
 |
 |
2 |
0.4 |
6.00E-04 |
NGF,
ENTPD2,
TXN2 |
positive regulation of nerve growth factor receptor signaling pathway [BP],
response to ozone [BP],
nerve growth factor processing [BP],
purine ribonucleoside diphosphate catabolic process [BP],
response to oxidative stress [BP],
nerve growth factor receptor binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_174_11 |
 |
 |
3 |
0.6 |
1.51E-04 |
EMR2,
C3AR1 |
C3a anaphylatoxin receptor activity [MF],
complement component C3a receptor activity [MF],
granulocyte chemotaxis [BP] |
| CG_ffipsc1911_promoter_n_PM_14_16_8 |
 |
 |
3 |
0.6 |
2.21E-05 |
PGLYRP2,
NLRC4 |
detection of bacterium [BP] |
| CG_ffipsc1911_promoter_n_PM_12_125_5 |
 |
 |
4 |
0.8 |
7.80E-05 |
PHB |
negative regulation of glucocorticoid receptor signaling pathway [BP] |
| CG_ffipsc1911_promoter_n_PM_12_38_9 |
 |
 |
2 |
0.4 |
1.24E-04 |
SLC25A29 |
acyl carnitine transmembrane transporter activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_263_4 |
 |
 |
3 |
0.6 |
9.40E-05 |
IL10 |
negative regulation of chronic inflammatory response to antigenic stimulus [BP],
negative regulation of interferon-alpha biosynthetic process [BP],
interleukin-10 receptor binding [MF],
negative regulation of myeloid dendritic cell activation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_79_6 |
 |
 |
1 |
0.2 |
1.88E-04 |
CHKA,
STX1A |
choline kinase activity [MF],
myosin head/neck binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_16_13 |
 |
 |
2 |
0.4 |
1.47E-04 |
NPC1 |
membrane raft [CC],
cellular response to low-density lipoprotein particle stimulus [BP] |
| CG_ffipsc1911_promoter_n_PM_16_45_18 |
 |
 |
4 |
0.8 |
5.33E-05 |
LOXL2,
VDR,
NTF4,
SLC9A7,
MESP1 |
negative regulation of endodermal cell fate specification [BP],
positive regulation of Notch signaling pathway involved in heart induction [BP],
protein deamination [BP],
cardiac atrium formation [BP],
vitamin D3 receptor activity [MF],
positive regulation of heart induction by negative regulation of canonical Wnt receptor signaling pathway [BP],
sensory organ boundary specification [BP],
ganglion mother cell fate determination [BP],
potassium:hydrogen antiporter activity [MF],
cardioblast migration to the midline involved in heart field formation [BP],
cardioblast anterior-lateral migration [BP],
sinoatrial node cell differentiation [BP],
growth involved in heart morphogenesis [BP],
sinus venosus morphogenesis [BP],
positive regulation of hepatocyte differentiation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_195_6 |
 |
 |
2 |
0.4 |
8.95E-05 |
GFAP,
ISYNA1,
MMS19,
KCNN4 |
inositol-3-phosphate synthase activity [MF],
stabilization of membrane potential [BP],
positive regulation of Schwann cell proliferation [BP],
phosphorelay signal transduction system [BP] |
| CG_ffipsc1911_promoter_n_PM_18_32_19 |
 |
 |
1 |
0.2 |
3.85E-05 |
FTCD |
formimidoyltetrahydrofolate cyclodeaminase activity [MF],
glutamate formimidoyltransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_3_4 |
 |
 |
2 |
0.4 |
1.27E-04 |
SSTR3 |
somatostatin signaling pathway [BP] |
| CG_ffipsc1911_promoter_n_PM_12_129_8 |
 |
 |
2 |
0.4 |
2.77E-05 |
AP3B1,
RNH1,
DMPK,
BCL2L1 |
regulation of excitatory postsynaptic membrane potential involved in skeletal muscle contraction [BP],
angiogenin-PRI complex [CC],
antigen processing and presentation, exogenous lipid antigen via MHC class Ib [BP],
response to cycloheximide [BP],
myosin phosphatase regulator activity [MF] |
| CG_ffipsc1911_promoter_n_PM_16_18_8 |
 |
 |
2 |
0.4 |
5.08E-05 |
STMN1,
BCL2,
ADAM10 |
constitutive protein ectodomain proteolysis [BP],
positive regulation of cellular component movement [BP],
negative regulation of cellular pH reduction [BP],
CD8-positive, alpha-beta T cell lineage commitment [BP],
positive regulation of neuron maturation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_197_4 |
 |
 |
2 |
0.4 |
3.26E-05 |
BDH1 |
3-hydroxybutyrate dehydrogenase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_86_8 |
 |
 |
2 |
0.4 |
2.48E-04 |
MAPK9 |
JUN kinase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_18_14_20 |
 |
 |
3 |
0.6 |
5.60E-05 |
GPCPD1,
AARS |
glycerophosphocholine phosphodiesterase activity [MF],
neuromuscular process controlling balance [BP] |
| CG_ffipsc1911_promoter_n_PM_12_204_6 |
 |
 |
1 |
0.2 |
1.94E-04 |
TRMT5 |
tRNA (guanine(37)-N(1))-methyltransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_1_5 |
 |
 |
2 |
0.4 |
4.24E-05 |
NLRP12 |
negative regulation of Toll signaling pathway [BP],
regulation of interleukin-18 biosynthetic process [BP] |
| CG_ffipsc1911_promoter_n_PM_14_19_12 |
 |
 |
4 |
0.8 |
7.31E-05 |
COQ3 |
2-polyprenyl-6-methoxy-1,4-benzoquinone methyltransferase activity [MF],
3-demethylubiquinone-9 3-O-methyltransferase activity [MF],
hexaprenyldihydroxybenzoate methyltransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_156_7 |
 |
 |
2 |
0.4 |
1.68E-05 |
MPC1,
LHX3 |
medial motor column neuron differentiation [BP],
pyruvate transmembrane transporter activity [MF],
mitochondrial pyruvate transport [BP] |
| CG_ffipsc1911_promoter_n_PM_12_196_7 |
 |
 |
2 |
0.4 |
4.05E-05 |
RBP3,
TRPT1 |
tRNA 2'-phosphotransferase activity [MF],
interphotoreceptor matrix [CC] |
| CG_ffipsc1911_promoter_n_PM_12_117_8 |
 |
 |
4 |
0.8 |
3.45E-04 |
CRYGC,
NPHP1 |
camera-type eye development [BP],
retina development in camera-type eye [BP] |
| CG_ffipsc1911_promoter_n_PM_16_2_6 |
 |
 |
4 |
0.8 |
6.48E-05 |
DLC1,
SPRY2,
ARAP3 |
negative regulation of Ras protein signal transduction [BP],
negative regulation of Rho protein signal transduction [BP] |
| CG_ffipsc1911_promoter_n_PM_14_68_6 |
 |
 |
4 |
0.8 |
4.49E-05 |
ACLY,
INTS1,
AGXT2L1 |
citrate lyase complex [CC],
ATP citrate synthase activity [MF],
ethanolamine-phosphate phospho-lyase activity [MF],
U2 snRNA 3'-end processing [BP] |
| CG_ffipsc1911_promoter_n_PM_14_72_3 |
 |
 |
2 |
0.4 |
3.31E-05 |
SERPINE2 |
mating plug formation [BP],
seminal vesicle epithelium development [BP] |
| CG_ffipsc1911_promoter_n_PM_12_150_9 |
 |
 |
2 |
0.4 |
3.17E-05 |
CYP1A1 |
flavonoid 3'-monooxygenase activity [MF],
dibenzo-p-dioxin catabolic process [BP],
insecticide metabolic process [BP] |
| CG_ffipsc1911_promoter_n_PM_12_39_10 |
 |
 |
2 |
0.4 |
2.35E-04 |
CHKA,
DPM1,
EPOR |
alcohol binding [MF],
choline kinase activity [MF],
erythropoietin receptor activity [MF],
erythropoietin-mediated signaling pathway [BP] |
| CG_ffipsc1911_promoter_n_PM_12_18_9 |
 |
 |
2 |
0.4 |
2.22E-04 |
CBS |
cystathionine beta-synthase activity [MF],
L-serine catabolic process [BP],
cysteine biosynthetic process via cystathionine [BP],
homocysteine catabolic process [BP],
transsulfuration [BP],
cysteine biosynthetic process from serine [BP],
hydrogen sulfide biosynthetic process [BP],
L-cysteine catabolic process [BP] |
| CG_ffipsc1911_promoter_n_PM_18_15_38 |
 |
 |
4 |
0.8 |
4.45E-05 |
SMG1,
ZNF607,
IDH3G,
DPF1,
TRIM26,
RNF168,
IGF2BP3,
TSC22D4,
HNF1B,
ADAMTS6,
TNIK,
PCGF2,
CREBBP,
POLN,
HDAC5,
HLTF,
ZNF132,
DIDO1,
SMURF2 |
zinc ion binding [MF],
chromatin modification [BP],
nucleus [CC] |
| CG_ffipsc1911_promoter_n_PM_12_24_5 |
 |
 |
1 |
0.2 |
1.10E-04 |
AHI1 |
pronephric nephron tubule morphogenesis [BP],
pronephric duct morphogenesis [BP],
Kupffer's vesicle development [BP] |
| CG_ffipsc1911_promoter_n_PM_12_23_7 |
 |
 |
2 |
0.4 |
8.33E-05 |
RORA,
CBS |
cGMP metabolic process [BP],
modified amino acid binding [MF],
cerebellum morphogenesis [BP] |
| CG_ffipsc1911_promoter_n_PM_12_239_7 |
 |
 |
3 |
0.6 |
4.16E-05 |
GPCPD1,
CELF1,
PGGT1B,
TXNL4A |
BRE binding [MF],
glycerophosphocholine phosphodiesterase activity [MF],
CAAX-protein geranylgeranyltransferase complex [CC],
spliceosomal complex assembly [BP],
CAAX-protein geranylgeranyltransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_14_5_7 |
 |
 |
3 |
0.6 |
1.76E-04 |
PKD1L1,
FASTK |
detection of nodal flow [BP],
Fas-activated serine/threonine kinase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_27_11 |
 |
 |
2 |
0.4 |
4.81E-05 |
BMP8B,
CD320,
HDGFRP3 |
growth factor activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_269_6 |
 |
 |
3 |
0.6 |
2.31E-05 |
P2RX1 |
external side of cell outer membrane [CC] |
| CG_ffipsc1911_promoter_n_PM_12_219_10 |
 |
 |
3 |
0.6 |
6.89E-05 |
DPYD |
dihydropyrimidine dehydrogenase (NADP+) activity [MF],
thymidine catabolic process [BP],
uracil catabolic process [BP],
thymine catabolic process [BP],
dihydroorotate oxidase activity [MF],
beta-alanine biosynthetic process [BP] |
| CG_ffipsc1911_promoter_n_PM_12_70_15 |
 |
 |
2 |
0.4 |
1.61E-04 |
NT5C2 |
nucleoside phosphotransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_18_23_25 |
 |
 |
4 |
0.8 |
6.18E-05 |
TBC1D4,
GRTP1,
TBC1D3 |
Rab GTPase activator activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_185_5 |
 |
 |
1 |
0.2 |
1.93E-04 |
NES,
SYNE4 |
integral to nuclear outer membrane [CC],
positive regulation of intermediate filament depolymerization [BP] |
| CG_ffipsc1911_promoter_n_PM_12_4_4 |
 |
 |
1 |
0.2 |
2.56E-04 |
PSIP1,
EIF2B4 |
response to heat [BP],
supercoiled DNA binding [MF] |
| CG_ffipsc1911_promoter_n_PM_16_19_17 |
 |
 |
4 |
0.8 |
3.74E-05 |
GTF2A2,
NACA |
TBP-class protein binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_83_6 |
 |
 |
2 |
0.4 |
4.41E-05 |
ABCB6,
SCIMP |
tetraspanin-enriched microdomain [CC],
uropod membrane [CC],
heme-transporting ATPase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_139_5 |
 |
 |
2 |
0.4 |
1.01E-04 |
LIPA,
PFKFB1 |
sterol esterase activity [MF],
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 complex [CC] |
| CG_ffipsc1911_promoter_n_PM_12_103_7 |
 |
 |
2 |
0.4 |
9.11E-06 |
TMEM123,
MSRB1 |
oncosis [BP],
methionine-R-sulfoxide reductase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_144_13 |
 |
 |
3 |
0.6 |
5.42E-05 |
SNX3,
HDAC4,
ELK4,
TECPR1,
ARPC5 |
phosphatidylinositol-3-phosphate binding [MF],
histone H3 deacetylation [BP],
histone deacetylation [BP],
actin cytoskeleton [CC],
actomyosin [CC] |
| CG_ffipsc1911_promoter_n_PM_16_14_14 |
 |
 |
4 |
0.8 |
6.54E-05 |
INSL3,
DMC1 |
oocyte maturation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_140_9 |
 |
 |
3 |
0.6 |
1.08E-04 |
ADAM17,
IRS2 |
JAK-STAT cascade involved in growth hormone signaling pathway [BP] |
| CG_ffipsc1911_promoter_n_PM_12_201_17 |
 |
 |
4 |
0.8 |
2.48E-04 |
TMEM86B |
alkenylglycerophosphocholine hydrolase activity [MF],
alkenylglycerophosphoethanolamine hydrolase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_91_5 |
 |
 |
2 |
0.4 |
1.40E-04 |
TMEM86B,
TACR2 |
prolactin secretion [BP],
alkenylglycerophosphocholine hydrolase activity [MF],
alkenylglycerophosphoethanolamine hydrolase activity [MF],
substance K receptor activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_230_8 |
 |
 |
3 |
0.6 |
1.44E-04 |
PKD1L3,
EIF2AK1 |
sour taste receptor activity [MF],
detection of chemical stimulus involved in sensory perception of sour taste [BP],
negative regulation of hemoglobin biosynthetic process [BP],
negative regulation of translational initiation by iron [BP],
regulation of eIF2 alpha phosphorylation by heme [BP] |
| CG_ffipsc1911_promoter_n_PM_14_46_10 |
 |
 |
5 |
0.8 |
7.35E-05 |
RACGAP1 |
cytokinesis, actomyosin contractile ring assembly [BP],
cytokinesis, initiation of separation [BP] |
| CG_ffipsc1911_promoter_n_PM_16_5_22 |
 |
 |
4 |
0.8 |
5.62E-05 |
RGS10 |
positive regulation of GTPase activity [BP] |
| CG_ffipsc1911_promoter_n_PM_12_202_5 |
 |
 |
4 |
0.8 |
1.59E-05 |
SEPT12,
GRIN2C |
directional locomotion [BP],
sperm annulus [CC] |
| CG_ffipsc1911_promoter_n_PM_12_240_11 |
 |
 |
2 |
0.4 |
5.88E-05 |
STX5,
STX1B |
retrograde transport, endosome to Golgi [BP],
SNAP receptor activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_55_5 |
 |
 |
2 |
0.4 |
2.26E-04 |
ABCB6 |
heme-transporting ATPase activity [MF],
detoxification of cadmium ion [BP] |
| CG_ffipsc1911_promoter_n_PM_12_28_5 |
 |
 |
4 |
0.8 |
1.27E-04 |
AGXT2L2,
RNF168,
PTCD1,
TP53AIP1,
SPHKAP,
SERAC1,
STARD7,
GP2,
ATPAF1 |
antigen transcytosis by M cells in mucosal-associated lymphoid tissue [BP],
histone H2A-K15 ubiquitination [BP],
histone H2A-K13 ubiquitination [BP],
mitochondrion [CC] |
| CG_ffipsc1911_promoter_n_PM_12_260_8 |
 |
 |
1 |
0.2 |
1.06E-04 |
PTK2 |
negative regulation of cell-cell adhesion [BP] |
| CG_ffipsc1911_promoter_n_PM_12_49_5 |
 |
 |
3 |
0.6 |
2.52E-04 |
ACD |
DNA polymerase binding [MF],
positive regulation of single-stranded telomeric DNA binding [BP] |
| CG_ffipsc1911_promoter_n_PM_12_224_7 |
 |
 |
2 |
0.4 |
1.54E-04 |
T,
DLC1 |
neural tube closure [BP] |
| CG_ffipsc1911_promoter_n_PM_14_32_4 |
 |
 |
1 |
0.2 |
1.29E-04 |
CYP51A1 |
cholesterol biosynthetic process via 24,25-dihydrolanosterol [BP],
sterol 14-demethylase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_126_7 |
 |
 |
4 |
0.8 |
3.13E-04 |
CTNNBIP1,
BDH1 |
3-hydroxybutyrate dehydrogenase activity [MF],
negative regulation of transcription initiation from RNA polymerase II promoter [BP],
regulation of vascular permeability involved in acute inflammatory response [BP] |
| CG_ffipsc1911_promoter_n_PM_14_31_5 |
 |
 |
2 |
0.4 |
5.69E-05 |
ALG3 |
dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_14_30_7 |
 |
 |
3 |
0.6 |
1.52E-05 |
MMP20,
PRC1 |
mitotic spindle elongation [BP],
regulation of enamel mineralization [BP] |
| CG_ffipsc1911_promoter_n_PM_12_180_6 |
 |
 |
4 |
0.8 |
1.32E-04 |
TCEB1,
TCEB2,
POLR2L |
regulation of transcription from RNA polymerase II promoter in response to hypoxia [BP],
positive regulation of viral transcription [BP],
transcription elongation from RNA polymerase II promoter [BP] |
| CG_ffipsc1911_promoter_n_PM_16_23_20 |
 |
 |
5 |
1.0 |
9.64E-05 |
DDX6,
ATXN2,
ADAM17,
STAT5B |
JAK-STAT cascade involved in growth hormone signaling pathway [BP],
cytoplasmic mRNA processing body assembly [BP] |
| CG_ffipsc1911_promoter_n_PM_16_41_7 |
 |
 |
1 |
0.2 |
9.14E-05 |
CHST10 |
HNK-1 sulfotransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_111_5 |
 |
 |
2 |
0.4 |
3.37E-05 |
MAN2B1,
VEGFC |
protein deglycosylation [BP],
positive regulation of lymphangiogenesis [BP],
positive regulation of mast cell chemotaxis [BP],
vascular endothelial growth factor receptor 3 binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_37_4 |
 |
 |
3 |
0.6 |
7.56E-05 |
ACOX3,
GNE,
HACL1 |
N-acylmannosamine kinase activity [MF],
UDP-N-acetylglucosamine 2-epimerase activity [MF],
peroxisomal matrix [CC] |
| CG_ffipsc1911_promoter_n_PM_16_31_18 |
 |
 |
1 |
0.2 |
7.00E-06 |
MTHFSD,
GRB2 |
Grb2-EGFR complex [CC],
5-formyltetrahydrofolate cyclo-ligase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_206_13 |
 |
 |
2 |
0.4 |
3.66E-05 |
TACR2,
UROC1,
ECHDC2 |
urocanate hydratase activity [MF],
substance K receptor activity [MF],
negative regulation of luteinizing hormone secretion [BP],
prolactin secretion [BP],
tachykinin receptor activity [MF],
intestine smooth muscle contraction [BP],
lyase activity [MF],
operant conditioning [BP],
positive regulation of acetylcholine secretion [BP] |
| CG_ffipsc1911_promoter_n_PM_12_128_9 |
 |
 |
2 |
0.4 |
4.33E-05 |
PPM1F,
FBP1,
PACSIN2,
NOX4 |
actin cytoskeleton organization [BP],
cellular response to drug [BP],
positive regulation of stress fiber assembly [BP] |
| CG_ffipsc1911_promoter_n_PM_12_63_11 |
 |
 |
4 |
0.8 |
1.34E-05 |
MMAB |
cob(I)yrinic acid a,c-diamide adenosyltransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_244_13 |
 |
 |
2 |
0.4 |
1.11E-05 |
OCA2 |
arsenite transport [BP],
tyrosine transport [BP],
arsenite transmembrane transporter activity [MF],
L-tyrosine transmembrane transporter activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_264_5 |
 |
 |
3 |
0.6 |
6.89E-05 |
MTOR,
TFDP2,
MYBBP1A,
ANP32A |
regulation of carbohydrate utilization [BP],
transcription factor binding [MF],
nucleocytoplasmic transport [BP],
NLS-dependent protein nuclear import complex [CC],
TFIIIC-class transcription factor binding [MF],
mTOR-FKBP12-rapamycin complex [CC],
cellular response to nutrient levels [BP] |
| CG_ffipsc1911_promoter_n_PM_12_120_9 |
 |
 |
1 |
0.2 |
4.91E-05 |
DPM3 |
integral to endoplasmic reticulum membrane [CC],
protein C-linked glycosylation via 2'-alpha-mannosyl-L-tryptophan [BP] |
| CG_ffipsc1911_promoter_n_PM_12_226_9 |
 |
 |
2 |
0.4 |
1.42E-04 |
DCTD,
HEY1,
AQP7 |
atrioventricular valve formation [BP],
dCMP deaminase activity [MF],
urea channel activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_193_5 |
 |
 |
2 |
0.4 |
1.47E-04 |
TFAP4,
GHRL,
BBS2,
GLG1,
PPP1R13L,
ACAA2,
TNFRSF18,
AXIN2 |
multicellular organism growth [BP],
cell death [BP],
positive regulation of multicellular organism growth [BP],
cartilage development [BP],
negative regulation of apoptotic process [BP],
response to hormone stimulus [BP],
regulation of chondrocyte differentiation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_6_10 |
 |
 |
2 |
0.4 |
4.25E-05 |
GCNT4 |
inter-male aggressive behavior [BP] |
| CG_ffipsc1911_promoter_n_PM_16_25_12 |
 |
 |
2 |
0.4 |
5.66E-05 |
ANKLE2,
LCT,
JUP |
gamma-catenin-TCF7L2 complex [CC],
structural constituent of cell wall [MF],
lactase activity [MF],
mitotic nuclear envelope reassembly [BP] |
| CG_ffipsc1911_promoter_n_PM_14_13_7 |
 |
 |
1 |
0.2 |
1.45E-04 |
HAGH |
hydroxyacylglutathione hydrolase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_16_17_22 |
 |
 |
4 |
0.8 |
5.87E-05 |
DDX58,
PDC,
NOS1 |
positive regulation of transcription factor import into nucleus [BP],
photoreceptor inner segment [CC] |
| CG_ffipsc1911_promoter_n_PM_12_47_10 |
 |
 |
3 |
0.6 |
6.89E-05 |
JAK3 |
response to interleukin-9 [BP],
response to interleukin-2 [BP],
negative regulation of T-helper 1 cell differentiation [BP],
negative regulation of dendritic cell cytokine production [BP],
negative regulation of FasL biosynthetic process [BP],
interleukin-4-mediated signaling pathway [BP] |
| CG_ffipsc1911_promoter_n_PM_12_93_6 |
 |
 |
2 |
0.4 |
1.34E-05 |
CSPG5 |
axon regeneration [BP] |
| CG_ffipsc1911_promoter_n_PM_12_199_8 |
 |
 |
2 |
0.4 |
1.36E-04 |
IL22RA2,
GNPTAB |
interleukin-22 binding [MF],
interleukin-22 receptor activity [MF],
carbohydrate phosphorylation [BP],
UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_25_4 |
 |
 |
2 |
0.4 |
4.63E-05 |
MARCH1,
CYP3A4,
SLC23A2,
MYL2,
EHD4 |
testosterone 6-beta-hydroxylase activity [MF],
L-ascorbate:sodium symporter activity [MF],
early endosome membrane [CC],
taurochenodeoxycholate 6alpha-hydroxylase activity [MF],
albendazole monooxygenase activity [MF],
sodium-dependent L-ascorbate transmembrane transporter activity [MF],
quinine 3-monooxygenase activity [MF],
L-ascorbic acid transport [BP],
transepithelial L-ascorbic acid transport [BP],
vitamin metabolic process [BP],
muscle cell fate specification [BP],
L-ascorbic acid transporter activity [MF],
molecular hydrogen transport [BP],
sodium-dependent multivitamin transmembrane transporter activity [MF] |
| CG_ffipsc1911_promoter_n_PM_14_26_10 |
 |
 |
2 |
0.4 |
7.17E-05 |
ANXA6,
FKBP1A,
ATP2A3,
CAMK2D |
regulation of ryanodine-sensitive calcium-release channel activity [BP],
calcium ion transport [BP],
sarcoplasmic reticulum membrane [CC],
sarcoplasmic reticulum [CC] |
| CG_ffipsc1911_promoter_n_PM_12_77_13 |
 |
 |
3 |
0.6 |
1.99E-04 |
BST2,
PKD1 |
negative regulation of egress of virus within host cell [BP],
metanephric distal tubule morphogenesis [BP],
negative regulation of plasmacytoid dendritic cell cytokine production [BP] |
| CG_ffipsc1911_promoter_n_PM_14_8_4 |
 |
 |
1 |
0.2 |
4.43E-05 |
YWHAG,
VAT1 |
protein kinase C inhibitor activity [MF],
negative regulation of mitochondrial fusion [BP] |
| CG_ffipsc1911_promoter_n_PM_12_237_7 |
 |
 |
4 |
0.8 |
9.28E-05 |
TPT1 |
negative regulation of ectoderm development [BP] |
| CG_ffipsc1911_promoter_n_PM_12_157_4 |
 |
 |
2 |
0.4 |
2.83E-04 |
FGF8 |
cell migration involved in mesendoderm migration [BP] |
| CG_ffipsc1911_promoter_n_PM_12_19_5 |
 |
 |
2 |
0.4 |
8.13E-05 |
NRAS,
ELMO1,
PLA2G1B,
POLR3C,
POLR1A |
actin cytoskeleton organization [BP],
Rac protein signal transduction [BP],
DNA-directed RNA polymerase activity [MF],
positive regulation of calcium ion transport into cytosol [BP] |
| CG_ffipsc1911_promoter_n_PM_12_76_10 |
 |
 |
2 |
0.4 |
1.20E-05 |
HVCN1,
ISYNA1,
PRICKLE1 |
inositol-3-phosphate synthase activity [MF],
negative regulation of cardiac muscle cell myoblast differentiation [BP],
voltage-gated proton channel activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_220_5 |
 |
 |
2 |
0.4 |
2.41E-05 |
KISS1,
FH |
fumarate hydratase activity [MF],
kisspeptin receptor binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_51_8 |
 |
 |
2 |
0.4 |
1.21E-04 |
ATP2B2,
MCOLN3,
ABCB4,
MYH10 |
ATPase activity, coupled to transmembrane movement of substances [MF],
otolith mineralization [BP],
auditory receptor cell differentiation [BP],
calcium-dependent ATPase activity [MF],
cerebellar Purkinje cell layer development [BP],
neuromuscular process controlling balance [BP] |
| CG_ffipsc1911_promoter_n_PM_14_76_17 |
 |
 |
5 |
0.8 |
7.64E-05 |
FRMD5,
ARRB1,
GNA12,
NOA1,
VIMP |
negative regulation of interleukin-6 production [BP],
heterotrimeric G-protein complex [CC],
extrinsic to membrane [CC],
GTP catabolic process [BP] |
| CG_ffipsc1911_promoter_n_PM_12_136_6 |
 |
 |
2 |
0.4 |
1.52E-04 |
NCKAP1,
CELSR1 |
apical protein localization [BP] |
| CG_ffipsc1911_promoter_n_PM_14_11_14 |
 |
 |
2 |
0.4 |
5.85E-05 |
KDM2B |
initiation of neural tube closure [BP] |
| CG_ffipsc1911_promoter_n_PM_12_130_10 |
 |
 |
2 |
0.4 |
3.09E-04 |
CC2D1B,
FEZF1 |
RNA polymerase II core promoter proximal region sequence-specific DNA binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_155_7 |
 |
 |
2 |
0.4 |
4.64E-05 |
AVP |
V1B vasopressin receptor binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_41_9 |
 |
 |
5 |
0.8 |
2.07E-04 |
ECE1 |
ear development [BP] |
| CG_ffipsc1911_promoter_n_PM_12_104_7 |
 |
 |
2 |
0.4 |
5.26E-05 |
SOD2,
PYGO1,
TRIP12 |
negative regulation of histone H2A K63-linked ubiquitination [BP],
post-embryonic development [BP],
vasodilation by acetylcholine involved in regulation of systemic arterial blood pressure [BP],
erythrophore differentiation [BP],
age-dependent response to reactive oxygen species [BP],
response to silicon dioxide [BP] |
| CG_ffipsc1911_promoter_n_PM_12_212_5 |
 |
 |
2 |
0.4 |
4.57E-05 |
QRFP,
SIRT2 |
orexigenic neuropeptide QRFP receptor binding [MF],
chromatin silencing at telomere [BP],
tubulin deacetylase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_14_74_8 |
 |
 |
2 |
0.4 |
5.26E-05 |
OAT,
GLO1 |
ornithine-oxo-acid transaminase activity [MF],
lactoylglutathione lyase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_18_27_18 |
 |
 |
3 |
0.6 |
2.85E-05 |
A4GALT,
PRKD1,
LARGE |
sphingolipid biosynthetic process [BP],
sphingolipid metabolic process [BP],
glycosphingolipid biosynthetic process [BP] |
| CG_ffipsc1911_promoter_n_PM_12_7_16 |
 |
 |
3 |
0.4 |
2.58E-04 |
NARFL,
GORASP1 |
CIA complex [CC],
mitotic prophase [BP] |
| CG_ffipsc1911_promoter_n_PM_16_46_18 |
 |
 |
4 |
0.8 |
3.17E-05 |
IRF7 |
interferon-alpha production [BP],
type I interferon biosynthetic process [BP] |
| CG_ffipsc1911_promoter_n_PM_12_43_6 |
 |
 |
2 |
0.4 |
8.61E-05 |
ADRB3 |
beta3-adrenergic receptor activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_149_4 |
 |
 |
1 |
0.2 |
1.87E-04 |
DOHH,
EPHA2,
GNE,
CLPX |
notochord cell development [BP],
mitochondrial endopeptidase Clp complex [CC],
N-acylmannosamine kinase activity [MF],
UDP-N-acetylglucosamine 2-epimerase activity [MF],
deoxyhypusine monooxygenase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_14_6_8 |
 |
 |
2 |
0.4 |
3.76E-05 |
TRMT2A,
ARHGAP1,
ERRFI1 |
RNA methyltransferase activity [MF],
Rho GTPase activator activity [MF] |
| CG_ffipsc1911_promoter_n_PM_16_38_11 |
 |
 |
3 |
0.6 |
5.45E-05 |
HLCS,
PC |
biotin binding [MF] |
| CG_ffipsc1911_promoter_n_PM_14_56_6 |
 |
 |
1 |
0.2 |
1.18E-05 |
SLC35A2,
GHRH |
growth hormone-releasing hormone activity [MF],
growth hormone-releasing hormone receptor binding [MF],
UDP-galactose transport [BP],
UDP-galactose transmembrane transporter activity [MF] |
| CG_ffipsc1911_promoter_n_PM_14_48_11 |
 |
 |
3 |
0.6 |
1.02E-04 |
TAT |
L-tyrosine:2-oxoglutarate aminotransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_132_7 |
 |
 |
3 |
0.6 |
2.55E-04 |
SIRT6,
PARP12 |
NAD+ ADP-ribosyltransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_16_22_31 |
 |
 |
3 |
0.6 |
7.52E-05 |
MYOZ1,
ACTN1 |
pseudopodium [CC] |
| CG_ffipsc1911_promoter_n_PM_12_254_6 |
 |
 |
2 |
0.4 |
3.44E-05 |
ECI2 |
dodecenoyl-CoA delta-isomerase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_8_8 |
 |
 |
2 |
0.4 |
1.67E-05 |
CDH17,
GPAM |
proton-dependent oligopeptide secondary active transmembrane transporter activity [MF],
negative regulation of activation-induced cell death of T cells [BP] |
| CG_ffipsc1911_promoter_n_PM_16_11_8 |
 |
 |
2 |
0.4 |
9.68E-05 |
PARP1 |
regulation of growth rate [BP],
protein poly-ADP-ribosylation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_251_4 |
 |
 |
3 |
0.6 |
9.68E-05 |
UBC,
RELN,
S100B,
ACSM1 |
memory [BP],
acyl-CoA ligase activity [MF],
long-term synaptic potentiation [BP],
benzoate metabolic process [BP],
hypothalamus gonadotrophin-releasing hormone neuron development [BP],
positive regulation of long-term synaptic potentiation [BP] |
| CG_ffipsc1911_promoter_n_PM_14_53_12 |
 |
 |
4 |
0.8 |
4.42E-05 |
LAMB2,
NES,
MAP2K2 |
metanephric glomerular basement membrane development [BP],
positive regulation of intermediate filament depolymerization [BP],
cell projection morphogenesis [BP],
peptidyl-serine autophosphorylation [BP] |
| CG_ffipsc1911_promoter_n_PM_14_33_7 |
 |
 |
2 |
0.4 |
2.71E-05 |
SOX15,
SLC2A5 |
myoblast development [BP],
positive regulation of satellite cell activation involved in skeletal muscle regeneration [BP],
fructose transmembrane transporter activity [MF],
fructose transport [BP] |
| CG_ffipsc1911_promoter_n_PM_12_123_7 |
 |
 |
2 |
0.4 |
1.37E-04 |
FUCA1,
RP9 |
signal recognition particle receptor complex [CC],
alpha-L-fucosidase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_231_8 |
 |
 |
2 |
0.4 |
9.65E-05 |
LCT,
CYP11A1,
ANGPT2 |
cholesterol monooxygenase (side-chain-cleaving) activity [MF],
maternal process involved in female pregnancy [BP],
negative regulation of positive chemotaxis [BP],
response to genistein [BP],
lactase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_45_7 |
 |
 |
2 |
0.4 |
1.92E-04 |
GOLGA8B,
NUP62,
MAN2B1,
GOLGA8A |
protein deglycosylation [BP],
nucleocytoplasmic shuttling complex [CC],
Golgi cisterna membrane [CC] |
| CG_ffipsc1911_promoter_n_PM_12_62_7 |
 |
 |
4 |
0.8 |
2.78E-04 |
KCNA2,
TBXA2R,
TBX3 |
atrioventricular bundle cell differentiation [BP],
sinoatrial node cell development [BP],
optic nerve structural organization [BP],
thromboxane A2 receptor activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_167_5 |
 |
 |
1 |
0.2 |
1.14E-04 |
TBX5 |
cell migration involved in coronary vasculogenesis [BP] |
| CG_ffipsc1911_promoter_n_PM_12_229_7 |
 |
 |
2 |
0.4 |
3.96E-04 |
BARD1,
RACGAP1 |
negative regulation of mRNA 3'-end processing [BP],
cytokinesis, actomyosin contractile ring assembly [BP],
cytokinesis, initiation of separation [BP],
BRCA1-BARD1 complex [CC] |
| CG_ffipsc1911_promoter_n_PM_12_74_7 |
 |
 |
4 |
0.6 |
6.61E-05 |
PTP4A2,
IDS |
iduronate-2-sulfatase activity [MF],
prenylated protein tyrosine phosphatase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_257_7 |
 |
 |
4 |
0.8 |
1.28E-04 |
TOMM20,
PAM16 |
protein targeting to mitochondrion [BP] |
| CG_ffipsc1911_promoter_n_PM_12_58_6 |
 |
 |
1 |
0.2 |
5.79E-06 |
ABCA2 |
regulation of intracellular cholesterol transport [BP] |
| CG_ffipsc1911_promoter_n_PM_12_84_8 |
 |
 |
1 |
0.2 |
1.71E-05 |
B3GNT8 |
poly-N-acetyllactosamine biosynthetic process [BP] |
| CG_ffipsc1911_promoter_n_PM_12_233_8 |
 |
 |
1 |
0.2 |
1.55E-04 |
FABP4,
PON3,
SNAI2 |
desmosome disassembly [BP],
3,4-dihydrocoumarin hydrolase activity [MF],
negative regulation of stem cell proliferation [BP],
phenylacetate catabolic process [BP],
dihydrocoumarin hydrolase activity [MF],
negative regulation of cell-cell adhesion by negative regulation of transcription from RNA polymerase II promoter [BP],
response to external stimulus [BP],
negative regulation of vitamin D receptor signaling pathway [BP],
white fat cell differentiation [BP] |
| CG_ffipsc1911_promoter_n_PM_16_1_42 |
 |
 |
6 |
1.0 |
6.63E-05 |
RRAGC,
RP9,
HNRNPU,
DHX16,
PHF5A,
ZCRB1 |
RNA splicing [BP] |
| CG_ffipsc1911_promoter_n_PM_12_179_11 |
 |
 |
2 |
0.4 |
7.05E-05 |
BCL2,
TNFRSF11B |
negative regulation of cellular pH reduction [BP],
negative regulation of odontogenesis of dentin-containing tooth [BP],
CD8-positive, alpha-beta T cell lineage commitment [BP],
positive regulation of neuron maturation [BP],
regulation of viral genome replication [BP] |
| CG_ffipsc1911_promoter_n_PM_12_13_15 |
 |
 |
3 |
0.6 |
5.95E-05 |
PRDX3,
BCL2L1 |
regulation of mitochondrial membrane potential [BP] |
| CG_ffipsc1911_promoter_n_PM_18_8_21 |
 |
 |
4 |
0.8 |
5.00E-06 |
AADAT,
VIMP |
regulation of nitric oxide metabolic process [BP],
2-aminoadipate transaminase activity [MF],
L-lysine catabolic process to acetyl-CoA via saccharopine [BP] |
| CG_ffipsc1911_promoter_n_PM_14_45_17 |
 |
 |
3 |
0.6 |
1.99E-05 |
KDM5B |
histone H3-K4 demethylation, trimethyl-H3-K4-specific [BP],
histone demethylase activity (H3-trimethyl-K4 specific) [MF],
histone demethylase activity (H3-dimethyl-K4 specific) [MF] |
| CG_ffipsc1911_promoter_n_PM_12_227_7 |
 |
 |
3 |
0.6 |
2.03E-05 |
PARP1 |
regulation of growth rate [BP],
protein poly-ADP-ribosylation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_56_5 |
 |
 |
1 |
0.2 |
3.27E-05 |
CYP26B1,
KDELR2,
ACSM1 |
acyl-CoA ligase activity [MF],
benzoate metabolic process [BP],
positive regulation of tongue muscle cell differentiation [BP],
butyrate metabolic process [BP],
KDEL sequence binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_54_4 |
 |
 |
3 |
0.6 |
9.25E-05 |
MYL3,
BRF1,
NKX2-5,
OCA2 |
proepicardium development [BP],
positive regulation of voltage-gated calcium channel activity [BP],
ventricular cardiac muscle tissue morphogenesis [BP],
transcription factor TFIIIB complex [CC],
L-tyrosine transmembrane transporter activity [MF],
Purkinje myocyte differentiation [BP],
arsenite transport [BP],
cardiac muscle tissue morphogenesis [BP],
atrioventricular node cell fate commitment [BP],
tyrosine transport [BP] |
| CG_ffipsc1911_promoter_n_PM_12_80_6 |
 |
 |
1 |
0.2 |
1.36E-05 |
ATE1 |
protein arginylation [BP],
arginyltransferase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_113_14 |
 |
 |
5 |
0.8 |
7.14E-05 |
DHX57,
HSPD1,
DGKI,
ADCY10,
FGF10,
MATK,
DHX29 |
positive regulation of urothelial cell proliferation [BP],
mesenchymal-epithelial cell signaling involved in lung development [BP],
positive regulation of T cell mediated immune response to tumor cell [BP],
positive regulation of white fat cell proliferation [BP],
urothelial cell proliferation [BP],
semicircular canal fusion [BP],
bronchiole morphogenesis [BP],
lung proximal/distal axis specification [BP],
positive regulation of Ras protein signal transduction [BP],
ATP binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_134_10 |
 |
 |
1 |
0.2 |
2.29E-05 |
TESC,
ATG3 |
Atg8 ligase activity [MF],
phosphatase inhibitor activity [MF],
Atg12 ligase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_191_10 |
 |
 |
2 |
0.4 |
1.58E-04 |
IPPK,
GHSR |
growth hormone secretagogue receptor activity [MF],
inositol phosphorylation [BP],
inositol pentakisphosphate 2-kinase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_225_5 |
 |
 |
2 |
0.4 |
3.37E-04 |
GSC,
GAS1 |
embryonic skeletal system morphogenesis [BP],
dorsal/ventral neural tube patterning [BP],
middle ear morphogenesis [BP] |
| CG_ffipsc1911_promoter_n_PM_12_95_7 |
 |
 |
3 |
0.6 |
1.26E-05 |
CACNA1S,
GRIK5,
DHRS7C |
regulation of synaptic vesicle fusion to presynaptic membrane [BP],
longitudinal sarcoplasmic reticulum [CC],
sarcoplasmic reticulum [CC] |
| CG_ffipsc1911_promoter_n_PM_14_10_19 |
 |
 |
2 |
0.4 |
1.78E-05 |
SGPP1,
JAK3 |
negative regulation of FasL biosynthetic process [BP],
sphingosine-1-phosphate phosphatase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_121_6 |
 |
 |
2 |
0.4 |
4.40E-04 |
VCPIP1 |
endoplasmic reticulum membrane fusion [BP],
Golgi reassembly [BP] |
| CG_ffipsc1911_promoter_n_PM_14_54_12 |
 |
 |
4 |
0.8 |
3.80E-05 |
HEY1,
PER1 |
protein binding transcription factor activity [MF] |
| CG_ffipsc1911_promoter_n_PM_16_29_10 |
 |
 |
4 |
0.8 |
7.35E-05 |
MASP2,
C3 |
complement activation, classical pathway [BP] |
| CG_ffipsc1911_promoter_n_PM_18_6_17 |
 |
 |
3 |
0.6 |
6.96E-05 |
GLI3 |
lambdoid suture morphogenesis [BP],
sagittal suture morphogenesis [BP],
lateral semicircular canal development [BP],
lateral ganglionic eminence cell proliferation [BP],
anterior semicircular canal development [BP] |
| CG_ffipsc1911_promoter_n_PM_12_205_12 |
 |
 |
5 |
0.8 |
3.66E-05 |
TH |
dopamine biosynthetic process from tyrosine [BP],
cellular response to manganese ion [BP],
tyrosine 3-monooxygenase activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_253_4 |
 |
 |
2 |
0.4 |
4.64E-05 |
SLC22A8 |
glutathione transport [BP] |
| CG_ffipsc1911_promoter_n_PM_12_161_4 |
 |
 |
3 |
0.6 |
7.19E-05 |
HIPK2 |
voluntary musculoskeletal movement [BP] |
| CG_ffipsc1911_promoter_n_PM_12_42_8 |
 |
 |
1 |
0.2 |
9.04E-05 |
DNASE2 |
deoxyribonuclease II activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_73_10 |
 |
 |
4 |
0.6 |
1.13E-04 |
CLASP1,
PPT1 |
protein depalmitoylation [BP],
palmitoyl-(protein) hydrolase activity [MF],
centrosomal corona [CC],
positive regulation of pinocytosis [BP],
cortical microtubule cytoskeleton [CC] |
| CG_ffipsc1911_promoter_n_PM_12_249_9 |
 |
 |
3 |
0.6 |
6.27E-06 |
ART4,
RGMA,
ANKLE2 |
anchored to membrane [CC],
mitotic nuclear envelope reassembly [BP] |
| CG_ffipsc1911_promoter_n_PM_12_242_12 |
 |
 |
2 |
0.4 |
1.33E-05 |
TMEM86B,
CHERP |
alkenylglycerophosphoethanolamine hydrolase activity [MF],
alkenylglycerophosphocholine hydrolase activity [MF],
positive regulation of NFAT protein import into nucleus [BP] |
| CG_ffipsc1911_promoter_n_PM_12_71_6 |
 |
 |
3 |
0.6 |
9.46E-05 |
PTCD1,
CCL24 |
eosinophil chemotaxis [BP],
tRNA 3'-end processing [BP] |
| CG_ffipsc1911_promoter_n_PM_12_164_8 |
 |
 |
2 |
0.4 |
6.81E-06 |
SLC38A7 |
L-asparagine transmembrane transporter activity [MF],
L-leucine transmembrane transporter activity [MF],
L-methionine transmembrane transporter activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_223_6 |
 |
 |
2 |
0.4 |
4.68E-05 |
TOPORS |
DNA topoisomerase binding [MF] |
| CG_ffipsc1911_promoter_n_PM_16_36_18 |
 |
 |
7 |
1.0 |
2.58E-05 |
RBM22,
STX2 |
calcium-dependent protein binding [MF] |
| CG_ffipsc1911_promoter_n_PM_12_209_12 |
 |
 |
4 |
0.8 |
3.07E-05 |
EXOSC3,
APRT,
LSM4 |
adenine binding [MF],
exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay [BP],
adenine phosphoribosyltransferase activity [MF],
nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay [BP],
U6 snRNP [CC] |
| CG_ffipsc1911_promoter_n_PM_14_70_13 |
 |
 |
2 |
0.4 |
3.09E-05 |
NOP14,
MAP2K2 |
Noc4p-Nop14p complex [CC],
peptidyl-serine autophosphorylation [BP] |
| CG_ffipsc1911_promoter_n_PM_12_141_10 |
 |
 |
3 |
0.6 |
2.65E-04 |
NLRP10 |
helper T cell enhancement of adaptive immune response [BP] |
| CG_ffipsc1911_promoter_n_PM_12_188_11 |
 |
 |
3 |
0.6 |
1.16E-05 |
KRT6A,
ELF5 |
ectoderm development [BP] |
| CG_ffipsc1911_promoter_n_PM_12_135_8 |
 |
 |
2 |
0.4 |
1.92E-04 |
SLC35B4 |
UDP-N-acetylglucosamine transmembrane transporter activity [MF],
UDP-xylose transport [BP],
UDP-N-acetylglucosamine transport [BP],
UDP-xylose transmembrane transporter activity [MF] |
| CG_ffipsc1911_promoter_n_PM_12_163_8 |
 |
 |
3 |
0.6 |
1.93E-04 |
CDIPT,
EIF2AK2 |
evasion or tolerance by virus of host immune response [BP],
CDP-diacylglycerol-inositol 3-phosphatidyltransferase activity [MF] |